-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

HC Wainwright & Co. Maintains Buy on Outlook Therapeutics, Lowers Price Target to $5

Benzinga · 01/06/2023 06:29
HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and lowers the price target from $6 to $5.